Morgan Stanley Voyager Therapeutics, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 380,485 shares of VYGR stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

380,485

Previous 447,141 14.91%

Holding current value

$1.23 Million

Previous $2.54 Million 49.27%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$3.38 - $6.04 $225,297 - $402,602	-66,656 Reduced 14.91%	380,485 $1.29 Million
Q4 2024 Feb 14, 2025	SELL	$5.27 - $8.07 $492,860 - $754,722	-93,522 Reduced 17.3%	447,141 $2.54 Million
Q3 2024 May 14, 2025	BUY	$5.77 - $9.27 $252,114 - $405,043	43,694 Added 8.79%	540,663 $3.16 Million
Q3 2024 Nov 14, 2024	BUY	$5.77 - $9.27 $252,114 - $405,043	43,694 Added 8.79%	540,663 $3.16 Million
Q2 2024 May 14, 2025	BUY	$7.42 - $10.54 $369,723 - $525,187	49,828 Added 11.14%	496,969 $3.93 Million
Q2 2024 Oct 17, 2024	BUY	$7.42 - $10.54 $1.59 Million - $2.26 Million	214,809 Added 76.13%	496,969 $3.93 Million
Q2 2024 Aug 14, 2024	BUY	$7.42 - $10.54 $1.59 Million - $2.26 Million	214,809 Added 76.13%	496,969 $3.93 Million
Q1 2024 Oct 17, 2024	SELL	$7.15 - $10.84 $1.54 Million - $2.33 Million	-214,809 Reduced 43.22%	282,160 $2.63 Million
Q1 2024 Aug 16, 2024	BUY	$7.15 - $10.84 $277,291 - $420,396	38,782 Added 15.93%	282,160 $2.63 Million
Q1 2024 May 15, 2024	BUY	$7.15 - $10.84 $277,291 - $420,396	38,782 Added 15.93%	282,160 $2.63 Million
Q4 2023 Aug 16, 2024	SELL	$6.28 - $8.81 $1.59 Million - $2.23 Million	-253,591 Reduced 51.03%	243,378 $2.05 Million
Q4 2023 Feb 13, 2024	SELL	$6.28 - $8.81 $317,931 - $446,015	-50,626 Reduced 17.22%	243,378 $2.05 Million
Q3 2023 Nov 15, 2023	SELL	$7.55 - $11.25 $3.69 Million - $5.5 Million	-489,066 Reduced 62.45%	294,004 $2.28 Million
Q2 2023 Aug 14, 2023	BUY	$6.94 - $13.99 $3.5 Million - $7.05 Million	503,903 Added 180.5%	783,070 $8.97 Million
Q1 2023 May 15, 2023	BUY	$6.0 - $10.78 $71,484 - $128,432	11,914 Added 4.46%	279,167 $2.15 Million
Q4 2022 Feb 14, 2023	SELL	$4.94 - $6.61 $396,188 - $530,122	-80,200 Reduced 23.08%	267,253 $1.63 Million
Q3 2022 Nov 14, 2022	BUY	$5.57 - $7.47 $1.23 Million - $1.64 Million	220,021 Added 172.66%	347,453 $2.06 Million
Q2 2022 Oct 27, 2022	SELL	$4.82 - $10.09 $114,571 - $239,839	-23,770 Reduced 15.72%	127,432 $753,000
Q2 2022 Aug 15, 2022	SELL	$4.82 - $10.09 $114,571 - $239,839	-23,770 Reduced 15.72%	127,432 $753,000
Q1 2022 Oct 27, 2022	BUY	$2.75 - $9.44 $65,367 - $224,388	23,770 Added 18.65%	151,202 $1.15 Million
Q1 2022 May 13, 2022	SELL	$2.75 - $9.44 $738,672 - $2.54 Million	-268,608 Reduced 63.98%	151,202 $1.15 Million
Q4 2021 Feb 14, 2022	SELL	$2.47 - $5.55 $487,029 - $1.09 Million	-197,178 Reduced 31.96%	419,810 $1.14 Million
Q3 2021 Nov 15, 2021	BUY	$2.63 - $4.12 $1.62 Million - $2.54 Million	616,988 New	616,988 $1.62 Million

Others Institutions Holding VYGR

# of Institutions

119

Shares Held

34.5M

Call Options Held

12.9K

Put Options Held

37.7K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $124M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account